| Erythromycin lactobionate 目录号 GC43627 |
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
-
Purity: >98.00%
- COA (Certificate Of Analysis)
- Datasheet
| Cas No. | 3847-29-8 | SDF | Download SDF |
| 别名 | N/A | ||
| 化学名 | 4-O-β-D-galactopyranosyl-D-gluconate erythromycin | ||
| Canonical SMILES | N/A | ||
| 分子式 | C37H67NO13•C12H22O12 | 分子量 | 1092.2 |
| 溶解度 | 1mg/mL in water | 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. | ||
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
||
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.[1] It is effective against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s range from 0.015-2.0 mg/l).[2] Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications.[3],[4] Erythromycin lactobionate is a soluble salt of erythromycin that is typically used for intraperitoneal or intravenous injections.[5],[6]
Reference:
[1]. Wilson, D.N. The A-Z of bacterial translation inhibitors. Crit. Rev. Biochem. Mol. Biol. 44(6), 393-433 (2009).
[2]. Kanatani, M.S., and Guglielmo, B.J. The new macrolides. Azithromycin and clarithromycin. Western J. Med. 160(1), 31-37 (1994).
[3]. Westphal, J.F. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycin. Br. J. Clin. Pharmacol. 50(4), 285-295 (2000).
[4]. Bibi, Z. Role of cytochrome P450 in drug interactions. Nutr. Metab. (Lond) 5(27), 1-10 (2008).
[5]. Hirakata, Y., Kaku, M., Tomono, K., et al. Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice. Antimicrobial Agents and Chemotherapy 36(6), 1198-1203 (1992).
[6]. Austin, K.L., Mather, L.E., Philpot, C.R., et al. Intersubject and dose-related variability after intravenous administration of erythromycin. British Journal of Clinical Pharmacology 10(3), 273-279 (1980).